Episode Details

South Carolina is set to pocket over $118,000 from a $29 million settlement with drugmaker Glenmark, accused of conspiring to inflate generic drug prices and stifle competition. This latest deal adds to nearly $70 million already recovered from similar cases against Lannett, Apotex, and others, bringing the total to over $96 million for states. The first major trial, expected late 2026, will focus on 80 topical generic drugs, with evidence including millions of documents and communications revealing coordinated price manipulation. Several executives are cooperating with authorities, and if you bought generic drugs from Glenmark, Lannett, Bausch, Apotex, or Heritage between May 2009 and December 2019, you may be eligible for compensation.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6bd3111bdb221b5a